ZEO ScientifiX tops $1M in April 2026 sales

ZEO ScientifiX, Inc. reported that unaudited sales for April 2026 surpassed $1 million in a single month for the first time in the Company’s history.

Rhea-AI Filing Summary

ZEO ScientifiX, Inc. reported that unaudited sales for April 2026 surpassed $1 million in a single month for the first time in the Company’s history. Management describes this as a commercial inflection point for its regenerative medicine products business serving physician-run clinics across the United States.

The Company attributes this milestone mainly to a newly implemented dedicated internal sales force and a “physician-first” commercial strategy. ZEO plans to hire additional full-time sales professionals to accelerate physician onboarding and deepen penetration in existing clinic networks, alongside expanding its physician education and masterclass programs.

Executives emphasize that breaking through the $1 million-per-month level acts as proof of concept for the model and that the existing sales and educational infrastructure is designed to support further growth, while reminding readers that these expectations are forward-looking and subject to risks and uncertainties.

Positive

• First-ever $1M sales month: Unaudited sales exceeded $1 million in April 2026, marking a new single‑month high and suggesting the company’s regenerative medicine commercial model is gaining traction.

Negative

• None.

Insights

Small-cap equity analyst

ZEO hits first-ever $1M sales month, signaling early commercial traction.

ZEO ScientifiX reports unaudited April 2026 sales above $1 million, its first single month at this level. For a regenerative medicine supplier focused on physician-run clinics, this indicates the commercial model is beginning to scale beyond early-stage testing.

Management links the milestone to a dedicated internal sales force and a physician-first, education-heavy strategy, including regenerative medicine masterclass programs. These elements suggest a repeatable go-to-market approach, though durability depends on continued physician adoption and clinic performance, as acknowledged in the forward-looking statements disclaimer.

Leadership plans to add more full-time sales professionals and expand educational initiatives, expecting physician count and revenue per account to rise in parallel. Subsequent filings detailing future monthly or quarterly revenue trends will be important for assessing whether this April 2026 result was a step-change or an early spike.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Monthly sales: Unaudited sales surpassed $1 million Announcement date: May 12, 2026 Trading venue: OTCQB: ZEOX

3 metrics

Monthly sales Unaudited sales surpassed $1 million Single month, April 2026

Announcement date May 12, 2026 Press release and 8-K filing date

Trading venue OTCQB: ZEOX Company’s quoted market designation

Key Terms

regenerative medicine, unaudited sales, physician-first commercial strategy, forward-looking statements, +1 more

5 terms

regenerative medicine medical

"a regenerative medicine products company serving physician-run clinics across the United States"

A field of medical treatments that aims to repair, replace or regenerate damaged tissues and organs using approaches such as cell or gene therapies, engineered tissues, and biologically active materials. It matters to investors because successful regenerative therapies can create entirely new, high-value markets and replace chronic treatments, offering large potential returns but also long development timelines, heavy regulation and high technical risk—like betting on a promising new technology that could either revolutionize care or fail in trials.

unaudited sales financial

"For the first time in Company history, ZEO’s single month unaudited sales surpassed the $1 million mark"

physician-first commercial strategy financial

"reflects the successful execution of a physician-first commercial strategy that we believe is uniquely positioned to scale"

forward-looking statements regulatory

"Certain statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

masterclass programs other

"including its ongoing regenerative medicine masterclass programs"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What milestone did ZEO ScientifiX (ZEOX) announce in April 2026?

ZEO ScientifiX announced that unaudited sales for April 2026 surpassed $1 million in a single month for the first time in its history, marking a key commercial milestone for its regenerative medicine products business serving physician‑run clinics.

How does ZEO ScientifiX (ZEOX) explain its April 2026 $1 million sales milestone?

Management attributes the April 2026 $1 million unaudited sales milestone to a newly implemented internal sales force and a physician‑first commercial strategy, which emphasizes close support for physician‑run clinics and structured educational initiatives in regenerative medicine.

What growth strategy is ZEO ScientifiX (ZEOX) pursuing after crossing $1 million in monthly sales?

After surpassing $1 million in unaudited April 2026 sales, ZEO ScientifiX plans to hire additional full‑time sales professionals, expand physician onboarding, and deepen penetration in existing clinic networks while continuing physician education and masterclass programs in regenerative medicine.

How important is physician education to ZEO ScientifiX (ZEOX) growth plans?

Physician education is central to ZEO ScientifiX’s strategy. The company runs regenerative medicine masterclass programs to teach clinical, operational, and practice‑development aspects, which management believes accelerates adoption, builds trust with clinicians, and supports sustainable account growth alongside its sales expansion.

Are ZEO ScientifiX (ZEOX) April 2026 sales figures audited or unaudited?

The April 2026 sales figure reported by ZEO ScientifiX is explicitly described as unaudited. The company states that single‑month unaudited sales surpassed the $1 million mark, and includes standard forward‑looking statements language about risks and uncertainties affecting future results.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/12/2026 - 10:09 AM Learn about SEC filing dates

false 0001557376 0001557376 2026-05-12 2026-05-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 12, 2026

ZEO SCIENTIFIX, INC.

(Exact name of registrant as specified in its charter)

Nevada		000-55008		47-4180540
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

3321 College Avenue, Suite 246 Davie, Florida		33314
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (888) 963-7881

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each Class		Trading Symbol		Name of each exchange on which registered
None		N/A		N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

As used in this Current Report on Form 8-K (this “Report”), and unless otherwise indicated, the terms “the Company,” “ZEO,” “we,” “us” and “our” refer to Zeo ScientifiX, Inc.

Item 8.01 Other Events.

On May 12, 2026, ZEO issued a press release announcing that it had achieved a significant milestone in that for the first time in Company history, ZEO’s single month unaudited sales surpassed the $1 million mark in April 2026.

A copy of the press release is included as Exhibit 99.1 to this Report.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release, dated May 12, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 12, 2026	ZEO SCIENTIFIX, INC.
	By:	/s/ Ian T. Bothwell
		Ian T. Bothwell Chief Executive Officer and Chief Financial Officer

2

Exhibit 99.1

FOR IMMEDIATE RELEASE

ZEO ScientifiX Announces That Unaudited Monthly Sales Surpassed $1.0 million in April 2026, the first time the Company has achieved this milestone.

FORT LAUDERDALE, FL – May 12, 2026 – ZEO ScientifiX (OTCQB: ZEOX) (“ZEO” or the “Company”), a regenerative medicine products company serving physician-run clinics across the United States, today announced that it had reached a defining commercial milestone. For the first time in Company history, ZEO’s single month unaudited sales surpassed the $1 million mark in April 2026. Management believes that this achievement marks a significant inflection point in ZEO’s growth trajectory and reflects the successful execution of a physician-first commercial strategy that we believe is uniquely positioned to scale.

At the core of this momentum is the Company’s newly implemented dedicated internal sales force. Building on this foundation, ZEO is actively looking to add additional full-time sales professionals to accelerate physician onboarding, broaden geographic reach, and deepen penetration within existing clinic networks. As ZEO scales its sales infrastructure, management expects physician count, revenue per account, and total Company revenue to grow in parallel.

Another significant driver of this momentum has been ZEO’s physician education strategy, including its ongoing regenerative medicine masterclass programs. These initiatives are designed to educate physicians and physician practices on the clinical, operational, and practice-development aspects of regenerative medicine. Management believes this physician-first education model has helped accelerate adoption, deepen trust with clinical partners, and support more sustainable account growth

Management Commentary

Ian Bothwell, Chief Executive Officer of ZEO ScientifiX, said, “April’s results represent a genuine inflection point for ZEO. Physicians across the country are actively seeking high-quality, differentiated solutions in the rapidly evolving market for regenerative medicine therapeutics, and our Company is meeting that demand at scale. The growth we are reporting we believe is not incidental. It reflects a deliberate build, and we are accelerating it.”

He added, “Our expanding sales force and our physician education initiatives are operating in parallel. We are not simply moving product. We are educating physicians, supporting practices, and helping clinicians build sustainable, high-performing regenerative medicine programs. That educational infrastructure, including our masterclass model, is a major reason this growth is beginning to compound.”

Sean Vega-Stanton, M.S., General Manager of ZEO ScientifiX, said, “Breaking through $1 million in a single month is not just a number. It is proof of concept. We continue to pursue strategies to expand our physician network, and we believe the next phase of growth will be larger than what we have already achieved. The infrastructure is in place. The market is ready. We are moving.”

About ZEO ScientifiX (OTCQB: ZEOX)

ZEO ScientifiX is a regenerative medicine products company dedicated to advancing patient outcomes through physician-run clinics. ZEO supplies cutting-edge biologics and regenerative therapies, partnering with clinicians to drive clinical excellence and sustainable practice growth.

Forward-Looking Statements

Certain statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Actual results could vary dramatically. ZEO has no intention and specifically disclaims any duty to update the information in this press release.

Media Contact:

ZEO ScientifiX, Inc.

Karlista Maroney

Director of Growth Strategy

IR@zeoscientifix.com

Filing Exhibits & Attachments

4 documents

Press Releases

• EX-99.1 EXHIBIT 99.1 8.9 KB

Other Documents

• EX-101 XBRL SCHEMA FILE 2.9 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB